CN114126643A - 包含溶菌酶的广谱抗菌药物制剂及其使用方法 - Google Patents
包含溶菌酶的广谱抗菌药物制剂及其使用方法 Download PDFInfo
- Publication number
- CN114126643A CN114126643A CN202080048142.9A CN202080048142A CN114126643A CN 114126643 A CN114126643 A CN 114126643A CN 202080048142 A CN202080048142 A CN 202080048142A CN 114126643 A CN114126643 A CN 114126643A
- Authority
- CN
- China
- Prior art keywords
- formulation
- lysozyme
- pharmaceutical formulation
- weight
- pharmaceutical
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
- 239000008194 pharmaceutical composition Substances 0.000 title claims abstract description 70
- 102000016943 Muramidase Human genes 0.000 title claims abstract description 67
- 108010014251 Muramidase Proteins 0.000 title claims abstract description 67
- 108010062010 N-Acetylmuramoyl-L-alanine Amidase Proteins 0.000 title claims abstract description 67
- 239000004325 lysozyme Substances 0.000 title claims abstract description 67
- 229960000274 lysozyme Drugs 0.000 title claims abstract description 67
- 235000010335 lysozyme Nutrition 0.000 title claims abstract description 67
- 238000000034 method Methods 0.000 title claims description 71
- 230000000845 anti-microbial effect Effects 0.000 title description 4
- 239000000203 mixture Substances 0.000 claims abstract description 106
- 238000009472 formulation Methods 0.000 claims abstract description 82
- 208000035143 Bacterial infection Diseases 0.000 claims abstract description 29
- 241000124008 Mammalia Species 0.000 claims abstract description 29
- 208000022362 bacterial infectious disease Diseases 0.000 claims abstract description 29
- 239000003814 drug Substances 0.000 claims abstract description 23
- 229940079593 drug Drugs 0.000 claims abstract description 20
- 208000036142 Viral infection Diseases 0.000 claims abstract description 17
- 230000009385 viral infection Effects 0.000 claims abstract description 17
- 208000025721 COVID-19 Diseases 0.000 claims abstract description 7
- 206010057190 Respiratory tract infections Diseases 0.000 claims abstract description 7
- 150000003839 salts Chemical class 0.000 claims description 46
- 239000002738 chelating agent Substances 0.000 claims description 33
- XLOMVQKBTHCTTD-UHFFFAOYSA-N Zinc monoxide Chemical compound [Zn]=O XLOMVQKBTHCTTD-UHFFFAOYSA-N 0.000 claims description 20
- 238000001356 surgical procedure Methods 0.000 claims description 20
- 230000003139 buffering effect Effects 0.000 claims description 18
- UIIMBOGNXHQVGW-UHFFFAOYSA-M Sodium bicarbonate Chemical compound [Na+].OC([O-])=O UIIMBOGNXHQVGW-UHFFFAOYSA-M 0.000 claims description 16
- 208000015181 infectious disease Diseases 0.000 claims description 16
- 239000011347 resin Substances 0.000 claims description 16
- 229920005989 resin Polymers 0.000 claims description 16
- 241000700605 Viruses Species 0.000 claims description 15
- 239000007864 aqueous solution Substances 0.000 claims description 13
- KCXVZYZYPLLWCC-UHFFFAOYSA-N EDTA Chemical compound OC(=O)CN(CC(O)=O)CCN(CC(O)=O)CC(O)=O KCXVZYZYPLLWCC-UHFFFAOYSA-N 0.000 claims description 12
- 239000011787 zinc oxide Substances 0.000 claims description 10
- 229960005336 magnesium citrate Drugs 0.000 claims description 8
- 239000004337 magnesium citrate Substances 0.000 claims description 8
- 235000002538 magnesium citrate Nutrition 0.000 claims description 8
- 239000006199 nebulizer Substances 0.000 claims description 8
- 235000017557 sodium bicarbonate Nutrition 0.000 claims description 8
- 229910000030 sodium bicarbonate Inorganic materials 0.000 claims description 8
- PLSARIKBYIPYPF-UHFFFAOYSA-H trimagnesium dicitrate Chemical compound [Mg+2].[Mg+2].[Mg+2].[O-]C(=O)CC(O)(CC([O-])=O)C([O-])=O.[O-]C(=O)CC(O)(CC([O-])=O)C([O-])=O PLSARIKBYIPYPF-UHFFFAOYSA-H 0.000 claims description 8
- 239000007910 chewable tablet Substances 0.000 claims description 6
- 229940068682 chewable tablet Drugs 0.000 claims description 6
- 241001678559 COVID-19 virus Species 0.000 claims description 4
- 241000711573 Coronaviridae Species 0.000 claims description 4
- 229920000615 alginic acid Polymers 0.000 claims description 4
- 235000010443 alginic acid Nutrition 0.000 claims description 4
- KRKNYBCHXYNGOX-UHFFFAOYSA-K Citrate Chemical compound [O-]C(=O)CC(O)(CC([O-])=O)C([O-])=O KRKNYBCHXYNGOX-UHFFFAOYSA-K 0.000 claims description 3
- 241000125945 Protoparvovirus Species 0.000 claims description 3
- 206010040047 Sepsis Diseases 0.000 claims description 3
- 150000001860 citric acid derivatives Chemical class 0.000 claims description 3
- 206010022000 influenza Diseases 0.000 claims description 3
- 241000701161 unidentified adenovirus Species 0.000 claims description 3
- 238000011282 treatment Methods 0.000 abstract description 26
- 241000894006 Bacteria Species 0.000 abstract description 16
- 230000000844 anti-bacterial effect Effects 0.000 abstract description 13
- 201000010099 disease Diseases 0.000 abstract description 6
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 abstract description 6
- 210000000056 organ Anatomy 0.000 abstract description 4
- 239000000546 pharmaceutical excipient Substances 0.000 abstract description 3
- 239000000825 pharmaceutical preparation Substances 0.000 abstract description 2
- 230000000241 respiratory effect Effects 0.000 abstract description 2
- 238000002560 therapeutic procedure Methods 0.000 abstract description 2
- 238000011866 long-term treatment Methods 0.000 abstract 1
- 230000009291 secondary effect Effects 0.000 abstract 1
- 230000000087 stabilizing effect Effects 0.000 description 38
- GHXZTYHSJHQHIJ-UHFFFAOYSA-N Chlorhexidine Chemical compound C=1C=C(Cl)C=CC=1NC(N)=NC(N)=NCCCCCCN=C(N)N=C(N)NC1=CC=C(Cl)C=C1 GHXZTYHSJHQHIJ-UHFFFAOYSA-N 0.000 description 33
- 229960003260 chlorhexidine Drugs 0.000 description 33
- 239000000843 powder Substances 0.000 description 19
- 230000001580 bacterial effect Effects 0.000 description 17
- 239000000243 solution Substances 0.000 description 15
- 206010061218 Inflammation Diseases 0.000 description 14
- 230000004054 inflammatory process Effects 0.000 description 14
- 208000032843 Hemorrhage Diseases 0.000 description 13
- 208000034158 bleeding Diseases 0.000 description 13
- 230000000740 bleeding effect Effects 0.000 description 13
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 13
- 230000000694 effects Effects 0.000 description 12
- 208000007565 gingivitis Diseases 0.000 description 12
- 238000011084 recovery Methods 0.000 description 12
- 230000002980 postoperative effect Effects 0.000 description 11
- 208000002193 Pain Diseases 0.000 description 10
- 238000000889 atomisation Methods 0.000 description 10
- 239000000796 flavoring agent Substances 0.000 description 10
- 230000036407 pain Effects 0.000 description 10
- KRKNYBCHXYNGOX-UHFFFAOYSA-N citric acid Chemical compound OC(=O)CC(O)(C(O)=O)CC(O)=O KRKNYBCHXYNGOX-UHFFFAOYSA-N 0.000 description 9
- 239000003086 colorant Substances 0.000 description 9
- 239000002504 physiological saline solution Substances 0.000 description 9
- 241000193403 Clostridium Species 0.000 description 8
- KDXKERNSBIXSRK-UHFFFAOYSA-N Lysine Natural products NCCCCC(N)C(O)=O KDXKERNSBIXSRK-UHFFFAOYSA-N 0.000 description 8
- 239000003242 anti bacterial agent Substances 0.000 description 8
- HVYWMOMLDIMFJA-DPAQBDIFSA-N cholesterol Chemical compound C1C=C2C[C@@H](O)CC[C@]2(C)[C@@H]2[C@@H]1[C@@H]1CC[C@H]([C@H](C)CCCC(C)C)[C@@]1(C)CC2 HVYWMOMLDIMFJA-DPAQBDIFSA-N 0.000 description 8
- 238000003384 imaging method Methods 0.000 description 8
- 230000003115 biocidal effect Effects 0.000 description 7
- 235000013355 food flavoring agent Nutrition 0.000 description 7
- 230000000670 limiting effect Effects 0.000 description 7
- 210000000214 mouth Anatomy 0.000 description 7
- 239000002324 mouth wash Substances 0.000 description 7
- 229940051866 mouthwash Drugs 0.000 description 7
- KDXKERNSBIXSRK-YFKPBYRVSA-N L-lysine Chemical compound NCCCC[C@H](N)C(O)=O KDXKERNSBIXSRK-YFKPBYRVSA-N 0.000 description 6
- 229940088710 antibiotic agent Drugs 0.000 description 6
- 239000004053 dental implant Substances 0.000 description 6
- 210000004072 lung Anatomy 0.000 description 6
- 239000003826 tablet Substances 0.000 description 6
- FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 description 5
- 241000194017 Streptococcus Species 0.000 description 5
- 210000002421 cell wall Anatomy 0.000 description 5
- 230000008859 change Effects 0.000 description 5
- 150000001875 compounds Chemical class 0.000 description 5
- 238000000605 extraction Methods 0.000 description 5
- 230000004044 response Effects 0.000 description 5
- 235000019640 taste Nutrition 0.000 description 5
- 210000001519 tissue Anatomy 0.000 description 5
- 206010006326 Breath odour Diseases 0.000 description 4
- 208000003322 Coinfection Diseases 0.000 description 4
- 241000192125 Firmicutes Species 0.000 description 4
- 239000002253 acid Substances 0.000 description 4
- 230000001154 acute effect Effects 0.000 description 4
- 238000011953 bioanalysis Methods 0.000 description 4
- 239000003795 chemical substances by application Substances 0.000 description 4
- 235000012000 cholesterol Nutrition 0.000 description 4
- 239000002158 endotoxin Substances 0.000 description 4
- 210000002429 large intestine Anatomy 0.000 description 4
- 229920006008 lipopolysaccharide Polymers 0.000 description 4
- 238000005259 measurement Methods 0.000 description 4
- 210000004379 membrane Anatomy 0.000 description 4
- 239000012528 membrane Substances 0.000 description 4
- 230000008447 perception Effects 0.000 description 4
- 230000002195 synergetic effect Effects 0.000 description 4
- 238000012360 testing method Methods 0.000 description 4
- 102000004190 Enzymes Human genes 0.000 description 3
- 108090000790 Enzymes Proteins 0.000 description 3
- 206010034133 Pathogen resistance Diseases 0.000 description 3
- 230000009471 action Effects 0.000 description 3
- 238000004458 analytical method Methods 0.000 description 3
- 230000008901 benefit Effects 0.000 description 3
- 210000004369 blood Anatomy 0.000 description 3
- 239000008280 blood Substances 0.000 description 3
- 230000003197 catalytic effect Effects 0.000 description 3
- 238000004090 dissolution Methods 0.000 description 3
- 239000012153 distilled water Substances 0.000 description 3
- 229940088598 enzyme Drugs 0.000 description 3
- 210000000987 immune system Anatomy 0.000 description 3
- 239000004615 ingredient Substances 0.000 description 3
- 230000004048 modification Effects 0.000 description 3
- 238000012986 modification Methods 0.000 description 3
- 208000028169 periodontal disease Diseases 0.000 description 3
- 238000011160 research Methods 0.000 description 3
- 210000002345 respiratory system Anatomy 0.000 description 3
- 230000014860 sensory perception of taste Effects 0.000 description 3
- 206010040872 skin infection Diseases 0.000 description 3
- 229940126586 small molecule drug Drugs 0.000 description 3
- 208000024891 symptom Diseases 0.000 description 3
- 239000007916 tablet composition Substances 0.000 description 3
- 229940124597 therapeutic agent Drugs 0.000 description 3
- 230000003612 virological effect Effects 0.000 description 3
- 102100036475 Alanine aminotransferase 1 Human genes 0.000 description 2
- 108010082126 Alanine transaminase Proteins 0.000 description 2
- 108010003415 Aspartate Aminotransferases Proteins 0.000 description 2
- 102000004625 Aspartate Aminotransferases Human genes 0.000 description 2
- 241000606125 Bacteroides Species 0.000 description 2
- BPYKTIZUTYGOLE-IFADSCNNSA-N Bilirubin Chemical compound N1C(=O)C(C)=C(C=C)\C1=C\C1=C(C)C(CCC(O)=O)=C(CC2=C(C(C)=C(\C=C/3C(=C(C=C)C(=O)N\3)C)N2)CCC(O)=O)N1 BPYKTIZUTYGOLE-IFADSCNNSA-N 0.000 description 2
- 241000193163 Clostridioides difficile Species 0.000 description 2
- 241000709661 Enterovirus Species 0.000 description 2
- 241000605909 Fusobacterium Species 0.000 description 2
- 108010010234 HDL Lipoproteins Proteins 0.000 description 2
- 102000015779 HDL Lipoproteins Human genes 0.000 description 2
- 206010061598 Immunodeficiency Diseases 0.000 description 2
- 108010007622 LDL Lipoproteins Proteins 0.000 description 2
- 102000007330 LDL Lipoproteins Human genes 0.000 description 2
- 241000186781 Listeria Species 0.000 description 2
- 208000032376 Lung infection Diseases 0.000 description 2
- 241000127282 Middle East respiratory syndrome-related coronavirus Species 0.000 description 2
- MSFSPUZXLOGKHJ-UHFFFAOYSA-N Muraminsaeure Natural products OC(=O)C(C)OC1C(N)C(O)OC(CO)C1O MSFSPUZXLOGKHJ-UHFFFAOYSA-N 0.000 description 2
- 108010013639 Peptidoglycan Proteins 0.000 description 2
- 206010035664 Pneumonia Diseases 0.000 description 2
- 241000605894 Porphyromonas Species 0.000 description 2
- 206010037660 Pyrexia Diseases 0.000 description 2
- 108010062497 VLDL Lipoproteins Proteins 0.000 description 2
- 239000004480 active ingredient Substances 0.000 description 2
- 239000002260 anti-inflammatory agent Substances 0.000 description 2
- 239000003899 bactericide agent Substances 0.000 description 2
- 235000021152 breakfast Nutrition 0.000 description 2
- 150000001768 cations Chemical class 0.000 description 2
- 210000000038 chest Anatomy 0.000 description 2
- 230000001684 chronic effect Effects 0.000 description 2
- 238000004040 coloring Methods 0.000 description 2
- DDRJAANPRJIHGJ-UHFFFAOYSA-N creatinine Chemical compound CN1CC(=O)NC1=N DDRJAANPRJIHGJ-UHFFFAOYSA-N 0.000 description 2
- 235000019634 flavors Nutrition 0.000 description 2
- 235000013305 food Nutrition 0.000 description 2
- 230000006870 function Effects 0.000 description 2
- 210000001035 gastrointestinal tract Anatomy 0.000 description 2
- 230000002070 germicidal effect Effects 0.000 description 2
- 125000003147 glycosyl group Chemical group 0.000 description 2
- 230000035876 healing Effects 0.000 description 2
- 230000036541 health Effects 0.000 description 2
- 230000036512 infertility Effects 0.000 description 2
- 230000002262 irrigation Effects 0.000 description 2
- 238000003973 irrigation Methods 0.000 description 2
- 230000002147 killing effect Effects 0.000 description 2
- 239000000463 material Substances 0.000 description 2
- 210000004877 mucosa Anatomy 0.000 description 2
- 230000002085 persistent effect Effects 0.000 description 2
- 239000003755 preservative agent Substances 0.000 description 2
- 230000002335 preservative effect Effects 0.000 description 2
- 230000001737 promoting effect Effects 0.000 description 2
- 235000019613 sensory perceptions of taste Nutrition 0.000 description 2
- 239000007787 solid Substances 0.000 description 2
- 238000011272 standard treatment Methods 0.000 description 2
- 239000000126 substance Substances 0.000 description 2
- 230000035923 taste sensation Effects 0.000 description 2
- 239000002562 thickening agent Substances 0.000 description 2
- 210000001685 thyroid gland Anatomy 0.000 description 2
- 230000007704 transition Effects 0.000 description 2
- FHVDTGUDJYJELY-UHFFFAOYSA-N 6-{[2-carboxy-4,5-dihydroxy-6-(phosphanyloxy)oxan-3-yl]oxy}-4,5-dihydroxy-3-phosphanyloxane-2-carboxylic acid Chemical compound O1C(C(O)=O)C(P)C(O)C(O)C1OC1C(C(O)=O)OC(OP)C(O)C1O FHVDTGUDJYJELY-UHFFFAOYSA-N 0.000 description 1
- 241000590020 Achromobacter Species 0.000 description 1
- 241000304886 Bacilli Species 0.000 description 1
- 241000193738 Bacillus anthracis Species 0.000 description 1
- 241000606124 Bacteroides fragilis Species 0.000 description 1
- 241000588807 Bordetella Species 0.000 description 1
- 241000588832 Bordetella pertussis Species 0.000 description 1
- 241000589969 Borreliella burgdorferi Species 0.000 description 1
- 241001453380 Burkholderia Species 0.000 description 1
- 241000589876 Campylobacter Species 0.000 description 1
- 241000589875 Campylobacter jejuni Species 0.000 description 1
- 241000222120 Candida <Saccharomycetales> Species 0.000 description 1
- 241000606161 Chlamydia Species 0.000 description 1
- 241000606153 Chlamydia trachomatis Species 0.000 description 1
- 241000193155 Clostridium botulinum Species 0.000 description 1
- 241000193468 Clostridium perfringens Species 0.000 description 1
- 241000186524 Clostridium subterminale Species 0.000 description 1
- 241000193449 Clostridium tetani Species 0.000 description 1
- 206010010741 Conjunctivitis Diseases 0.000 description 1
- 206010011224 Cough Diseases 0.000 description 1
- XUIIKFGFIJCVMT-GFCCVEGCSA-N D-thyroxine Chemical compound IC1=CC(C[C@@H](N)C(O)=O)=CC(I)=C1OC1=CC(I)=C(O)C(I)=C1 XUIIKFGFIJCVMT-GFCCVEGCSA-N 0.000 description 1
- 208000002064 Dental Plaque Diseases 0.000 description 1
- 208000000059 Dyspnea Diseases 0.000 description 1
- 206010013975 Dyspnoeas Diseases 0.000 description 1
- 238000002965 ELISA Methods 0.000 description 1
- 241000196324 Embryophyta Species 0.000 description 1
- 241000588724 Escherichia coli Species 0.000 description 1
- 241000186394 Eubacterium Species 0.000 description 1
- 241001468125 Exiguobacterium Species 0.000 description 1
- 241000589565 Flavobacterium Species 0.000 description 1
- 241000605986 Fusobacterium nucleatum Species 0.000 description 1
- 102000017011 Glycated Hemoglobin A Human genes 0.000 description 1
- 102000005744 Glycoside Hydrolases Human genes 0.000 description 1
- 108010031186 Glycoside Hydrolases Proteins 0.000 description 1
- 241000193159 Hathewaya histolytica Species 0.000 description 1
- 241000282412 Homo Species 0.000 description 1
- 102000004157 Hydrolases Human genes 0.000 description 1
- 108090000604 Hydrolases Proteins 0.000 description 1
- 206010020751 Hypersensitivity Diseases 0.000 description 1
- 208000029462 Immunodeficiency disease Diseases 0.000 description 1
- 241000588747 Klebsiella pneumoniae Species 0.000 description 1
- CKLJMWTZIZZHCS-REOHCLBHSA-N L-aspartic acid Chemical compound OC(=O)[C@@H](N)CC(O)=O CKLJMWTZIZZHCS-REOHCLBHSA-N 0.000 description 1
- 241000186660 Lactobacillus Species 0.000 description 1
- 241000186869 Lactobacillus salivarius Species 0.000 description 1
- 241000186779 Listeria monocytogenes Species 0.000 description 1
- 206010025080 Lung consolidation Diseases 0.000 description 1
- 206010025102 Lung infiltration Diseases 0.000 description 1
- 241000351643 Metapneumovirus Species 0.000 description 1
- 241000563924 Mitu Species 0.000 description 1
- 241000588771 Morganella <proteobacterium> Species 0.000 description 1
- 241000186359 Mycobacterium Species 0.000 description 1
- 241000187479 Mycobacterium tuberculosis Species 0.000 description 1
- MNLRQHMNZILYPY-MDMHTWEWSA-N N-acetyl-alpha-D-muramic acid Chemical compound OC(=O)[C@@H](C)O[C@H]1[C@H](O)[C@@H](CO)O[C@H](O)[C@@H]1NC(C)=O MNLRQHMNZILYPY-MDMHTWEWSA-N 0.000 description 1
- OVRNDRQMDRJTHS-FMDGEEDCSA-N N-acetyl-beta-D-glucosamine Chemical group CC(=O)N[C@H]1[C@H](O)O[C@H](CO)[C@@H](O)[C@@H]1O OVRNDRQMDRJTHS-FMDGEEDCSA-N 0.000 description 1
- 241000588653 Neisseria Species 0.000 description 1
- 241000588652 Neisseria gonorrhoeae Species 0.000 description 1
- 206010030113 Oedema Diseases 0.000 description 1
- 208000002606 Paramyxoviridae Infections Diseases 0.000 description 1
- 208000037581 Persistent Infection Diseases 0.000 description 1
- 206010034972 Photosensitivity reaction Diseases 0.000 description 1
- 241000709664 Picornaviridae Species 0.000 description 1
- 241000605862 Porphyromonas gingivalis Species 0.000 description 1
- 241000605861 Prevotella Species 0.000 description 1
- 241000165031 Pseudomonas lactis Species 0.000 description 1
- 208000035415 Reinfection Diseases 0.000 description 1
- 241000725643 Respiratory syncytial virus Species 0.000 description 1
- 206010062106 Respiratory tract infection viral Diseases 0.000 description 1
- 241000315672 SARS coronavirus Species 0.000 description 1
- 241000607142 Salmonella Species 0.000 description 1
- 206010039438 Salmonella Infections Diseases 0.000 description 1
- 241000131808 Scolopendra Species 0.000 description 1
- 241000605036 Selenomonas Species 0.000 description 1
- 241000607768 Shigella Species 0.000 description 1
- 206010040943 Skin Ulcer Diseases 0.000 description 1
- 241000191940 Staphylococcus Species 0.000 description 1
- 241000191967 Staphylococcus aureus Species 0.000 description 1
- 241000191963 Staphylococcus epidermidis Species 0.000 description 1
- 241000194026 Streptococcus gordonii Species 0.000 description 1
- 241000194019 Streptococcus mutans Species 0.000 description 1
- 241000194025 Streptococcus oralis Species 0.000 description 1
- 241000193998 Streptococcus pneumoniae Species 0.000 description 1
- 241000194023 Streptococcus sanguinis Species 0.000 description 1
- 241000193987 Streptococcus sobrinus Species 0.000 description 1
- 239000004098 Tetracycline Substances 0.000 description 1
- 102000011923 Thyrotropin Human genes 0.000 description 1
- 108010061174 Thyrotropin Proteins 0.000 description 1
- 241000589886 Treponema Species 0.000 description 1
- XSQUKJJJFZCRTK-UHFFFAOYSA-N Urea Chemical compound NC(N)=O XSQUKJJJFZCRTK-UHFFFAOYSA-N 0.000 description 1
- LEHOTFFKMJEONL-UHFFFAOYSA-N Uric Acid Chemical compound N1C(=O)NC(=O)C2=C1NC(=O)N2 LEHOTFFKMJEONL-UHFFFAOYSA-N 0.000 description 1
- TVWHNULVHGKJHS-UHFFFAOYSA-N Uric acid Natural products N1C(=O)NC(=O)C2NC(=O)NC21 TVWHNULVHGKJHS-UHFFFAOYSA-N 0.000 description 1
- 241000607598 Vibrio Species 0.000 description 1
- 241000607626 Vibrio cholerae Species 0.000 description 1
- 239000013543 active substance Substances 0.000 description 1
- 230000002411 adverse Effects 0.000 description 1
- 229940072056 alginate Drugs 0.000 description 1
- 230000000202 analgesic effect Effects 0.000 description 1
- 229940035676 analgesics Drugs 0.000 description 1
- 239000000730 antalgic agent Substances 0.000 description 1
- 229940121363 anti-inflammatory agent Drugs 0.000 description 1
- 229940124599 anti-inflammatory drug Drugs 0.000 description 1
- 230000002421 anti-septic effect Effects 0.000 description 1
- 229940124350 antibacterial drug Drugs 0.000 description 1
- 208000006673 asthma Diseases 0.000 description 1
- 229940065181 bacillus anthracis Drugs 0.000 description 1
- 201000007032 bacterial conjunctivitis Diseases 0.000 description 1
- 239000003139 biocide Substances 0.000 description 1
- 230000006696 biosynthetic metabolic pathway Effects 0.000 description 1
- 235000019658 bitter taste Nutrition 0.000 description 1
- 238000004820 blood count Methods 0.000 description 1
- 238000009640 blood culture Methods 0.000 description 1
- 230000001680 brushing effect Effects 0.000 description 1
- 239000004202 carbamide Substances 0.000 description 1
- 210000004027 cell Anatomy 0.000 description 1
- 230000004637 cellular stress Effects 0.000 description 1
- 238000002512 chemotherapy Methods 0.000 description 1
- 229940038705 chlamydia trachomatis Drugs 0.000 description 1
- 229940045373 chlorhexidine mouthwash Drugs 0.000 description 1
- 238000004140 cleaning Methods 0.000 description 1
- 238000003776 cleavage reaction Methods 0.000 description 1
- 206010009887 colitis Diseases 0.000 description 1
- 230000000052 comparative effect Effects 0.000 description 1
- 238000007796 conventional method Methods 0.000 description 1
- 229940109239 creatinine Drugs 0.000 description 1
- 239000013078 crystal Substances 0.000 description 1
- 230000009089 cytolysis Effects 0.000 description 1
- 230000006378 damage Effects 0.000 description 1
- 230000006735 deficit Effects 0.000 description 1
- 239000008367 deionised water Substances 0.000 description 1
- 229910021641 deionized water Inorganic materials 0.000 description 1
- 239000002274 desiccant Substances 0.000 description 1
- 238000011161 development Methods 0.000 description 1
- 206010012601 diabetes mellitus Diseases 0.000 description 1
- 238000010586 diagram Methods 0.000 description 1
- 208000007784 diverticulitis Diseases 0.000 description 1
- 238000001647 drug administration Methods 0.000 description 1
- 238000001035 drying Methods 0.000 description 1
- 239000007938 effervescent tablet Substances 0.000 description 1
- 238000002635 electroconvulsive therapy Methods 0.000 description 1
- 239000003792 electrolyte Substances 0.000 description 1
- 230000008030 elimination Effects 0.000 description 1
- 238000003379 elimination reaction Methods 0.000 description 1
- 238000004836 empirical method Methods 0.000 description 1
- 230000002255 enzymatic effect Effects 0.000 description 1
- 210000003743 erythrocyte Anatomy 0.000 description 1
- 210000003238 esophagus Anatomy 0.000 description 1
- 238000011156 evaluation Methods 0.000 description 1
- 230000007717 exclusion Effects 0.000 description 1
- 230000006355 external stress Effects 0.000 description 1
- 239000000945 filler Substances 0.000 description 1
- 238000001914 filtration Methods 0.000 description 1
- 239000003205 fragrance Substances 0.000 description 1
- 230000002068 genetic effect Effects 0.000 description 1
- 210000001905 globus pallidus Anatomy 0.000 description 1
- 150000004676 glycans Chemical class 0.000 description 1
- 108091005995 glycated hemoglobin Proteins 0.000 description 1
- 210000005255 gram-positive cell Anatomy 0.000 description 1
- 230000007062 hydrolysis Effects 0.000 description 1
- 238000006460 hydrolysis reaction Methods 0.000 description 1
- 230000007813 immunodeficiency Effects 0.000 description 1
- 230000008595 infiltration Effects 0.000 description 1
- 238000001764 infiltration Methods 0.000 description 1
- 230000002757 inflammatory effect Effects 0.000 description 1
- 230000000977 initiatory effect Effects 0.000 description 1
- 239000002198 insoluble material Substances 0.000 description 1
- 230000000968 intestinal effect Effects 0.000 description 1
- 210000000936 intestine Anatomy 0.000 description 1
- 238000001990 intravenous administration Methods 0.000 description 1
- 230000003907 kidney function Effects 0.000 description 1
- 229940039696 lactobacillus Drugs 0.000 description 1
- 230000002475 laxative effect Effects 0.000 description 1
- 150000002632 lipids Chemical group 0.000 description 1
- 239000006194 liquid suspension Substances 0.000 description 1
- 230000003908 liver function Effects 0.000 description 1
- 230000007774 longterm Effects 0.000 description 1
- 230000002101 lytic effect Effects 0.000 description 1
- 238000004519 manufacturing process Methods 0.000 description 1
- 230000010534 mechanism of action Effects 0.000 description 1
- 230000004060 metabolic process Effects 0.000 description 1
- 229910052751 metal Inorganic materials 0.000 description 1
- 239000002184 metal Substances 0.000 description 1
- 238000001531 micro-dissection Methods 0.000 description 1
- 210000004400 mucous membrane Anatomy 0.000 description 1
- 238000002663 nebulization Methods 0.000 description 1
- 230000007935 neutral effect Effects 0.000 description 1
- 231100000957 no side effect Toxicity 0.000 description 1
- 230000008520 organization Effects 0.000 description 1
- 230000003204 osmotic effect Effects 0.000 description 1
- 150000003904 phospholipids Chemical class 0.000 description 1
- 230000036211 photosensitivity Effects 0.000 description 1
- 229920001282 polysaccharide Polymers 0.000 description 1
- 239000005017 polysaccharide Substances 0.000 description 1
- 238000002360 preparation method Methods 0.000 description 1
- 230000008569 process Effects 0.000 description 1
- 238000011321 prophylaxis Methods 0.000 description 1
- 235000018102 proteins Nutrition 0.000 description 1
- 102000004169 proteins and genes Human genes 0.000 description 1
- 108090000623 proteins and genes Proteins 0.000 description 1
- 238000012797 qualification Methods 0.000 description 1
- 230000007115 recruitment Effects 0.000 description 1
- 208000023504 respiratory system disease Diseases 0.000 description 1
- 208000020029 respiratory tract infectious disease Diseases 0.000 description 1
- 238000003757 reverse transcription PCR Methods 0.000 description 1
- 210000003296 saliva Anatomy 0.000 description 1
- 206010039447 salmonellosis Diseases 0.000 description 1
- 230000007017 scission Effects 0.000 description 1
- 238000004062 sedimentation Methods 0.000 description 1
- 230000035945 sensitivity Effects 0.000 description 1
- 208000026425 severe pneumonia Diseases 0.000 description 1
- 230000035939 shock Effects 0.000 description 1
- 231100000075 skin burn Toxicity 0.000 description 1
- 231100000019 skin ulcer Toxicity 0.000 description 1
- 238000007711 solidification Methods 0.000 description 1
- 230000008023 solidification Effects 0.000 description 1
- 239000002904 solvent Substances 0.000 description 1
- 239000007921 spray Substances 0.000 description 1
- 239000003381 stabilizer Substances 0.000 description 1
- 239000008223 sterile water Substances 0.000 description 1
- 210000002784 stomach Anatomy 0.000 description 1
- 229940031000 streptococcus pneumoniae Drugs 0.000 description 1
- 238000007920 subcutaneous administration Methods 0.000 description 1
- 239000000758 substrate Substances 0.000 description 1
- 208000011580 syndromic disease Diseases 0.000 description 1
- 230000009885 systemic effect Effects 0.000 description 1
- 230000008685 targeting Effects 0.000 description 1
- 235000019364 tetracycline Nutrition 0.000 description 1
- 150000003522 tetracyclines Chemical class 0.000 description 1
- 229940040944 tetracyclines Drugs 0.000 description 1
- 230000001225 therapeutic effect Effects 0.000 description 1
- 229940034208 thyroxine Drugs 0.000 description 1
- XUIIKFGFIJCVMT-UHFFFAOYSA-N thyroxine-binding globulin Natural products IC1=CC(CC([NH3+])C([O-])=O)=CC(I)=C1OC1=CC(I)=C(O)C(I)=C1 XUIIKFGFIJCVMT-UHFFFAOYSA-N 0.000 description 1
- 238000004448 titration Methods 0.000 description 1
- 230000000699 topical effect Effects 0.000 description 1
- 238000012546 transfer Methods 0.000 description 1
- 150000003626 triacylglycerols Chemical class 0.000 description 1
- 229940116269 uric acid Drugs 0.000 description 1
- 238000005353 urine analysis Methods 0.000 description 1
- 229940118696 vibrio cholerae Drugs 0.000 description 1
- 210000001835 viscera Anatomy 0.000 description 1
- 229910000859 α-Fe Inorganic materials 0.000 description 1
- 150000003952 β-lactams Chemical class 0.000 description 1
Images
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- A61K38/43—Enzymes; Proenzymes; Derivatives thereof
- A61K38/46—Hydrolases (3)
- A61K38/47—Hydrolases (3) acting on glycosyl compounds (3.2), e.g. cellulases, lactases
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/02—Inorganic compounds
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
- A61K47/16—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing nitrogen, e.g. nitro-, nitroso-, azo-compounds, nitriles, cyanates
- A61K47/18—Amines; Amides; Ureas; Quaternary ammonium compounds; Amino acids; Oligopeptides having up to five amino acids
- A61K47/183—Amino acids, e.g. glycine, EDTA or aspartame
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/0053—Mouth and digestive tract, i.e. intraoral and peroral administration
- A61K9/0056—Mouth soluble or dispersible forms; Suckable, eatable, chewable coherent forms; Forms rapidly disintegrating in the mouth; Lozenges; Lollipops; Bite capsules; Baked products; Baits or other oral forms for animals
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/007—Pulmonary tract; Aromatherapy
- A61K9/0073—Sprays or powders for inhalation; Aerolised or nebulised preparations generated by other means than thermal energy
- A61K9/0078—Sprays or powders for inhalation; Aerolised or nebulised preparations generated by other means than thermal energy for inhalation via a nebulizer such as a jet nebulizer, ultrasonic nebulizer, e.g. in the form of aqueous drug solutions or dispersions
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Veterinary Medicine (AREA)
- Medicinal Chemistry (AREA)
- Epidemiology (AREA)
- Pharmacology & Pharmacy (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Gastroenterology & Hepatology (AREA)
- Immunology (AREA)
- General Chemical & Material Sciences (AREA)
- Oil, Petroleum & Natural Gas (AREA)
- Inorganic Chemistry (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Otolaryngology (AREA)
- Dispersion Chemistry (AREA)
- Pulmonology (AREA)
- Physiology (AREA)
- Dermatology (AREA)
- Nutrition Science (AREA)
- Zoology (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Medicinal Preparation (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201962853215P | 2019-05-28 | 2019-05-28 | |
| US62/853,215 | 2019-05-28 | ||
| PCT/IB2020/055083 WO2020240472A1 (en) | 2019-05-28 | 2020-05-28 | Wide-spectrum antibacterial pharmaceutical formulations comprising lysozyme and methods of using the same |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| CN114126643A true CN114126643A (zh) | 2022-03-01 |
Family
ID=73551002
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CN202080048142.9A Pending CN114126643A (zh) | 2019-05-28 | 2020-05-28 | 包含溶菌酶的广谱抗菌药物制剂及其使用方法 |
Country Status (12)
| Country | Link |
|---|---|
| US (3) | US20200376094A1 (enExample) |
| EP (1) | EP3976093A4 (enExample) |
| JP (3) | JP7768769B2 (enExample) |
| CN (1) | CN114126643A (enExample) |
| AR (1) | AR119031A1 (enExample) |
| BR (1) | BR112021024001A2 (enExample) |
| CA (1) | CA3145530A1 (enExample) |
| CO (1) | CO2021017958A2 (enExample) |
| IL (1) | IL288531A (enExample) |
| MX (1) | MX2021014634A (enExample) |
| TW (1) | TW202110474A (enExample) |
| WO (1) | WO2020240472A1 (enExample) |
Families Citing this family (4)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN112805027B (zh) * | 2020-04-27 | 2023-10-10 | 广州新创忆药物临床研究有限公司 | 一种抗新冠病毒感染的药物与应用 |
| WO2021217702A1 (zh) * | 2020-04-27 | 2021-11-04 | 广州新创忆药物临床研究有限公司 | 一种预防或治疗covid-19新冠肺炎的药物、食物及其应用 |
| WO2023133412A2 (en) * | 2022-01-05 | 2023-07-13 | Prophase Labs, Inc. | Compositions having synergistic anti-viral action and methods for treating coronavirus |
| CN114503981A (zh) * | 2022-01-07 | 2022-05-17 | 上海膜益信息科技有限公司 | 一种不分层防霉液及其制备方法和应用 |
Citations (4)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN1557485A (zh) * | 2004-01-30 | 2004-12-29 | 大连帝恩生物工程有限公司 | 基因重组人溶菌酶在消除病原微生物感染炎症上的应用 |
| UA48016U (ru) * | 2010-01-25 | 2010-02-25 | Илона Васильевна Ковач | Способ профилактики кариеса зубов у детей 3-6 лет |
| UA68612U (ru) * | 2012-02-07 | 2012-03-26 | Дмитрий Викторович Дудар | Способ лечения хронического рецидивирующего афтозного стоматита у больных целиакией |
| CN107899006A (zh) * | 2017-11-28 | 2018-04-13 | 四川清舒乐科技有限公司 | 冲洗鼻腔的药物组合物及其制备方法 |
Family Cites Families (9)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| DK501686A (da) * | 1986-10-20 | 1988-04-21 | Otto Melchior Poulsen | Enzymholdigt, baktericidt middel samt tandplejemidler og saarbehandlingsmidler, som indeholder det |
| PT1755576E (pt) * | 2004-04-08 | 2011-10-19 | Dermcare Vet Pty Ltd | Composições antimicrobianas e métodos para a sua utilização |
| CN1583170A (zh) * | 2004-06-10 | 2005-02-23 | 安米 | 用于抗病毒抗耐药菌的人溶菌酶药物及其制法 |
| US20080095754A1 (en) * | 2006-10-18 | 2008-04-24 | Burke Susan E | Ophthalmic compositions comprising diglycine |
| US8097434B2 (en) * | 2007-10-19 | 2012-01-17 | Becton, Dickinson And Company | Methods for the detection of beta-lactamases |
| CN102223876A (zh) * | 2008-09-26 | 2011-10-19 | 纳米生物公司 | 纳米乳剂治疗性组合物及其使用方法 |
| CN111973484A (zh) * | 2013-03-12 | 2020-11-24 | 普莱玛疗法公司 | 包含螯合剂和碱的牙用组合物 |
| JP7055814B2 (ja) * | 2017-02-28 | 2022-04-18 | プリシジョンバイオティクス・グループ・リミテッド | 呼吸器ウイルス感染症に対する免疫応答を有利に調節することができるビフィドバクテリウム・ロンガム |
| US20200215169A1 (en) * | 2017-07-17 | 2020-07-09 | The Henry M. Jackson Foundation For The Advancement Of Military Medicine, Inc. | Antibacterial methods and related kits |
-
2020
- 2020-05-28 AR ARP200101510A patent/AR119031A1/es unknown
- 2020-05-28 US US16/885,537 patent/US20200376094A1/en not_active Abandoned
- 2020-05-28 BR BR112021024001A patent/BR112021024001A2/pt unknown
- 2020-05-28 CN CN202080048142.9A patent/CN114126643A/zh active Pending
- 2020-05-28 WO PCT/IB2020/055083 patent/WO2020240472A1/en not_active Ceased
- 2020-05-28 JP JP2021571513A patent/JP7768769B2/ja active Active
- 2020-05-28 CA CA3145530A patent/CA3145530A1/en active Pending
- 2020-05-28 TW TW109117916A patent/TW202110474A/zh unknown
- 2020-05-28 MX MX2021014634A patent/MX2021014634A/es unknown
- 2020-05-28 EP EP20815355.1A patent/EP3976093A4/en not_active Withdrawn
-
2021
- 2021-11-29 IL IL288531A patent/IL288531A/en unknown
- 2021-12-28 CO CONC2021/0017958A patent/CO2021017958A2/es unknown
-
2022
- 2022-07-28 US US17/875,872 patent/US20220362354A1/en not_active Abandoned
-
2023
- 2023-11-09 US US18/505,472 patent/US20240066105A1/en active Pending
-
2024
- 2024-12-10 JP JP2024215483A patent/JP2025038034A/ja active Pending
-
2025
- 2025-10-30 JP JP2025183379A patent/JP2026021451A/ja active Pending
Patent Citations (4)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN1557485A (zh) * | 2004-01-30 | 2004-12-29 | 大连帝恩生物工程有限公司 | 基因重组人溶菌酶在消除病原微生物感染炎症上的应用 |
| UA48016U (ru) * | 2010-01-25 | 2010-02-25 | Илона Васильевна Ковач | Способ профилактики кариеса зубов у детей 3-6 лет |
| UA68612U (ru) * | 2012-02-07 | 2012-03-26 | Дмитрий Викторович Дудар | Способ лечения хронического рецидивирующего афтозного стоматита у больных целиакией |
| CN107899006A (zh) * | 2017-11-28 | 2018-04-13 | 四川清舒乐科技有限公司 | 冲洗鼻腔的药物组合物及其制备方法 |
Non-Patent Citations (2)
| Title |
|---|
| KO KY等: "Ethylenediaminetetraacetate and lysozyme improves antimicrobial activities of ovotransferrin against Escherichia coli O157:H7", POULT SCI, pages 406 - 414 * |
| 赵电波等: "天然生物防腐剂溶菌酶的改性研究进展", 中国食品添加剂, no. 05, pages 200 - 204 * |
Also Published As
| Publication number | Publication date |
|---|---|
| US20200376094A1 (en) | 2020-12-03 |
| TW202110474A (zh) | 2021-03-16 |
| BR112021024001A2 (pt) | 2022-01-25 |
| WO2020240472A1 (en) | 2020-12-03 |
| CO2021017958A2 (es) | 2022-01-17 |
| EP3976093A4 (en) | 2023-07-05 |
| AR119031A1 (es) | 2021-11-17 |
| CA3145530A1 (en) | 2020-12-03 |
| US20240066105A1 (en) | 2024-02-29 |
| EP3976093A1 (en) | 2022-04-06 |
| JP2026021451A (ja) | 2026-02-10 |
| JP2025038034A (ja) | 2025-03-18 |
| IL288531A (en) | 2022-01-01 |
| JP7768769B2 (ja) | 2025-11-12 |
| MX2021014634A (es) | 2022-07-04 |
| US20220362354A1 (en) | 2022-11-17 |
| JP2022534776A (ja) | 2022-08-03 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| US20240066105A1 (en) | Wide-spectrum antibacterial pharmaceutical formulations comprising lysozyme and methods of using the same | |
| Cegolon et al. | Nasal disinfection for the prevention and control of COVID-19: A scoping review on potential chemo-preventive agents | |
| US20090252708A1 (en) | Biotherapeutic compositions comprising probiotic escherichia coli and uses thereof | |
| JP5996553B2 (ja) | 果実および／または野菜との口腔接触に起因する口腔アレルギー症状の表面適用による予防および／または処置のための調製物 | |
| EA008612B1 (ru) | Способ лечения обычной простуды, аллергического ринита и инфекций дыхательных путей | |
| CA2982943C (en) | Compositions and methods for treating bacterial infection | |
| Elkin et al. | Pseudomonal infection in cystic fibrosis: the battle continues | |
| WO2007065482A1 (en) | Use of transferrins for treating destructive inflammation of mucous membrane | |
| US20200352986A1 (en) | Methods and compositions for alleviating respiratory dysfunction | |
| UA126993C2 (uk) | Композиція для ерадикації helicobacter pylori | |
| EP2956153A1 (en) | Treatment of evolving bacterial resistance diseases including klebsiella pneumoniae with liposomally formulated glutathione | |
| JP7854397B2 (ja) | 微生物感染治療のためのプロテアーゼ製剤 | |
| Nickles et al. | Evaluation of two siblings with Papillon‐Lefèvre syndrome 5 years after treatment of periodontitis in primary and mixed dentition | |
| EP4076396A2 (en) | Solution and method for reducing the virulence of microbes | |
| RU2762506C1 (ru) | Средство для аппликации полости рта и носа и способ его применения в составе комплексной терапии инфекционно-воспалительных заболеваний носовой и ротовой полости | |
| JP2004529095A (ja) | 抗菌性ｉｂ−３６７ペプチドの経口投与による人工呼吸器関連性肺炎の予防法 | |
| RU2526121C1 (ru) | Способ лечения больных туберкулезом легких с сопутствующими неспецифическими бронхитами | |
| JPH0327313A (ja) | 生理的用量のビタミンａと治療活性のある各種有効成分とを有する組成物 | |
| Sriudom et al. | Comparison of gargling and swabbing methods for delivering pre-procedural povidone-iodine mouthrinse: a randomised crossover trial | |
| JP4949224B2 (ja) | 薬物除去剤及び薬物除去促進剤 | |
| Dilworth | Antifungal: Oral and oesophogeal candidiasis | |
| WO2025179171A1 (en) | Ingestible nutritive compositions with prebiotics, probiotics, and postbiotics | |
| EA052469B1 (ru) | Лечение некистозных фиброзных (немуковисцидозных) бронхоэктазов | |
| US9408883B2 (en) | Essential oil of Kunzea ambigua and methods of use | |
| ALSOFYANI et al. | Use of Oral Antiseptics and its Association with Cardiovascular Events |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| PB01 | Publication | ||
| PB01 | Publication | ||
| SE01 | Entry into force of request for substantive examination | ||
| SE01 | Entry into force of request for substantive examination | ||
| WD01 | Invention patent application deemed withdrawn after publication |
Application publication date: 20220301 |
|
| WD01 | Invention patent application deemed withdrawn after publication |